A phase II trial of aprepitant, palonosetron, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting for gynecological cancer.
Latest Information Update: 12 May 2016
Price :
$35 *
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Olanzapine (Primary) ; Palonosetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 08 Oct 2013 New trial record